ESR1 and breast carcinoma: Specifically, we identified three lipid metabolites—myristoleate (14:1n5), tricosanoyl sphingomyelin (d18:1/23:0), and 5α-androstan-3β,17β-diol monosulfate (2)—that demonstrated significant and reproducible causal associations with ER+ breast cancer after FDR correction.